# A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)

> **NCT02078960** · PHASE1,PHASE2 · TERMINATED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Omacetaxine mepesuccinate

## Key facts

- **NCT ID:** NCT02078960
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10-09
- **Primary completion:** 2017-07-06
- **Final completion:** 2017-11-27
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Inability to accrue additional sites and enroll an adequate number of subjects.
- **Last updated:** 2021-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02078960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02078960, "A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02078960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*